Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
This article was originally published in The Pink Sheet Daily
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
You may also be interested in...
Depomed deems increased buyout offer from Horizon as insufficient, possibly leaving Horizon to consider alternative acquisitions. Valeant will pay $1bn to acquire Sprout and its just approved female sexual desire disorder drug Addyi.
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.
With reams of PCSK9 data showing robust lowering of LDL – a trusted surrogate – under their belt, sponsors aim to win over prescribers, payers and patients ahead of outcomes trial releases.